| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 1 | +166K | 28.4% | $373.73 | +$61.9M |
| Sells | 11 | -418K | 71.6% | $372.49 | -$156M |
| Net | -10 | -253K | -43.3% | -$94M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Baker Bros. Advisors Lp | Director | $764M | +$61.9M | +8.82% | Aug 18, 2025 |
| Rebecca Taub | Director | $364M | -$27.8M | -7.1% | Aug 11, 2025 |
| Paul A. Friedman | Director | $268M | -$75.1M | -21.9% | Aug 13, 2025 |
| Fred B. Craves | Director | $123M | -$5.08M | -3.98% | Mar 12, 2025 |
| William John Sibold | President and CEO, Director | $86.3M | -$8.2M | -8.68% | Dec 3, 2025 |
| Richard S. Levy | Director | $11.2M | -$4.43M | -28.3% | Nov 13, 2025 |
| Mardi Dier | EVP and CFO | $6.22M | -$3.13M | -33.5% | Dec 2, 2025 |
| Alex G. Howarth | Chief Financial Officer | $5.74M | Jan 23, 2024 | ||
| Carole Huntsman | Chief Commercial Officer | $5.66M | -$1.8M | -24.1% | Nov 21, 2025 |
| Brian J. Lynch | SVP and General Counsel | $5.33M | Jan 23, 2024 | ||
| Remy Sukhija | Chief Commercial Officer | $3.66M | Jan 16, 2023 | ||
| Shannon T. Kelley | General Counsel | $3.45M | -$694K | -16.7% | Aug 18, 2025 |
| David Soergel | Chief Medical Officer | $2.57M | May 15, 2025 | ||
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | $2M | -$5.39M | -73% | Mar 5, 2025 |
| Kenneth Bate | Director | $1.29M | -$18.8M | -93.6% | Nov 5, 2025 |
| James M. Daly | Director | $713K | -$5.38M | -88.3% | Jun 20, 2025 |
| Bay City Capital Llc | 10%+ Owner | $308K | Dec 3, 2021 | ||
| Jacqualyn A. Fouse | Director | $298K | Jun 20, 2025 | ||
| Daniel J. Brennan | Director | $293K | Aug 1, 2025 | ||
| Raymond Cheong | Director | Jun 15, 2023 | |||
| Keith R. Gollust | Director | Jun 16, 2022 | |||
| David Milligan | Director | Jun 16, 2022 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|